caa a22 4500 606234772 CHVBK 20210128101239.0 cr unu---uuuuu 210128e20151101xx s 000 0 eng 10.1007/s11010-015-2521-0 doi (NATIONALLICENCE)springer-10.1007/s11010-015-2521-0 High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients [Elektronische Daten] [Zhuoxing Liu, Kunpeng Wu, Zhixiong Yang, Aibing Wu] Our previous study showed that knockdown of high-mobility group A2 (HMGA2) could suppress nasopharyngeal carcinoma (NPC) cell migration, invasion, and epithelial-mesenchymal transition (EMT) process, and HMGA2 is a direct functional target of let-7 to regulate NPC cell migration, invasion, and EMT process. However, little is known about the clinical and prognostic significance of HMGA2 protein in NPC patients. The purpose of this study is to identify the clinical and prognostic roles of HMGA2 in NPC patients. We initially analyzed the microarray data and verified mRNA and protein levels of HMGA2 in NPC tissues. Immunohistochemical staining for HMGA2 protein was performed in 116 NPC patients. The associations between HMGA2 protein expression and clinicopathologic features and its prognostic significance were analyzed. In our results, we found mRNA and protein expressions of HMGA2 were upregulated in NPC tissues and cell lines. In 116 NPC tissue samples, we observed that HMGA2 protein overexpression was associated with clinical stage, lymph node metastasis, and distant metastasis. Moreover, NPC patients with high levels of HMGA2 protein expression had shorter overall survival in comparison to patients with low levels of HMGA2 protein. In multivariate analysis, HMGA2 protein overexpression was an unfavorable prognostic factor for NPC patients. In conclusion, HMGA2 is an important biomarker to predicting NPC patient's survival time. Springer Science+Business Media New York, 2015 High-mobility group A2 nationallicence Nasopharyngeal carcinoma nationallicence Prognosis nationallicence Immunohistochemistry nationallicence Biomarker nationallicence Liu Zhuoxing Cancer Center, Heyuan People's Hospital, No. 733 Wenxiang Road, 517000, Heyuan, Guangdong, People's Republic of China aut Wu Kunpeng Cancer Center, Heyuan People's Hospital, No. 733 Wenxiang Road, 517000, Heyuan, Guangdong, People's Republic of China aut Yang Zhixiong Cancer Center, Affiliated Hospital of Guangdong Medical College, No. 57 People's Avenue South, 524002, Zhanjiang, Guangdong, People's Republic of China aut Wu Aibing Cancer Center, Affiliated Hospital of Guangdong Medical College, No. 57 People's Avenue South, 524002, Zhanjiang, Guangdong, People's Republic of China aut Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 409/1-2(2015-11-01), 155-162 0300-8177 409:1-2<155 2015 409 11010 https://doi.org/10.1007/s11010-015-2521-0 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s11010-015-2521-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Liu Zhuoxing Cancer Center, Heyuan People's Hospital, No. 733 Wenxiang Road, 517000, Heyuan, Guangdong, People's Republic of China aut NATIONALLICENCE 700 1- Wu Kunpeng Cancer Center, Heyuan People's Hospital, No. 733 Wenxiang Road, 517000, Heyuan, Guangdong, People's Republic of China aut NATIONALLICENCE 700 1- Yang Zhixiong Cancer Center, Affiliated Hospital of Guangdong Medical College, No. 57 People's Avenue South, 524002, Zhanjiang, Guangdong, People's Republic of China aut NATIONALLICENCE 700 1- Wu Aibing Cancer Center, Affiliated Hospital of Guangdong Medical College, No. 57 People's Avenue South, 524002, Zhanjiang, Guangdong, People's Republic of China aut NATIONALLICENCE 773 0- Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 409/1-2(2015-11-01), 155-162 0300-8177 409:1-2<155 2015 409 11010